Enochian Biosciences, Inc.
NASDAQ: ENOB0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mark R. Dybul
- Employees
- 22
- Headquarters
- Los Angeles, United States
- IPO year
- 2018
- Market cap
- $45.4M
- Website
- https://www.enochianbio.com
Loading ENOB…
Loading profile data…Frequently asked questions about ENOB
What does Enochian Biosciences, Inc. (ENOB) do?
Enochian Biosciences, Inc. is a pre-clinical biotechnology firm dedicated to the research and advancement of novel pharmaceutical and biological agents. Its primary focus lies in developing treatments for a range of human diseases, including human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza, coronavirus infections, and vario...
Where does ENOB trade?
Enochian Biosciences, Inc. (ENOB) trades on the NASDAQ Capital Market.
What sector is ENOB in?
Enochian Biosciences, Inc. (ENOB) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Enochian Biosciences, Inc.?
Mark R. Dybul is the chief executive officer of Enochian Biosciences, Inc. (ENOB).
Where is Enochian Biosciences, Inc. headquartered?
Enochian Biosciences, Inc. is headquartered in United States.
Does ENOB pay a dividend?
Enochian Biosciences, Inc. (ENOB) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ENOB go public?
Enochian Biosciences, Inc. (ENOB) completed its initial public offering in 2018.